186 related articles for article (PubMed ID: 38152402)
1. Unique characteristics of the tumor immune microenvironment in young patients with metastatic colorectal cancer.
Griffith BD; Lazarus J; McGue J; Krishnan S; D'Angelica MI; Shia J; Dobrosotskaya I; Shi J; Edwards J; Rao A; Frankel TL
Front Immunol; 2023; 14():1289402. PubMed ID: 38152402
[TBL] [Abstract][Full Text] [Related]
2. Mathematical Modeling of the Metastatic Colorectal Cancer Microenvironment Defines the Importance of Cytotoxic Lymphocyte Infiltration and Presence of PD-L1 on Antigen Presenting Cells.
Lazarus J; Oneka MD; Barua S; Maj T; Lanfranca MP; Delrosario L; Sun L; Smith JJ; D'Angelica MI; Shia J; Fang JM; Shi J; Di Magliano MP; Zou W; Rao A; Frankel TL
Ann Surg Oncol; 2019 Sep; 26(9):2821-2830. PubMed ID: 31250346
[TBL] [Abstract][Full Text] [Related]
3. Spatial and phenotypic immune profiling of metastatic colon cancer.
Lazarus J; Maj T; Smith JJ; Perusina Lanfranca M; Rao A; D'Angelica MI; Delrosario L; Girgis A; Schukow C; Shia J; Kryczek I; Shi J; Wasserman I; Crawford H; Nathan H; Pasca Di Magliano M; Zou W; Frankel TL
JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429368
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.
Rosenbaum MW; Bledsoe JR; Morales-Oyarvide V; Huynh TG; Mino-Kenudson M
Mod Pathol; 2016 Sep; 29(9):1104-12. PubMed ID: 27198569
[TBL] [Abstract][Full Text] [Related]
5. RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1.
Burren S; Reche K; Blank A; Galvàn JA; Dawson H; Berger MD; Zlobec I; Lugli A
Pathol Res Pract; 2021 Jul; 223():153486. PubMed ID: 34051513
[TBL] [Abstract][Full Text] [Related]
6. Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer.
Qin A; Lima F; Bell S; Kalemkerian GP; Schneider BJ; Ramnath N; Lew M; Krishnan S; Mohammed S; Rao A; Frankel TL
Sci Rep; 2022 May; 12(1):9054. PubMed ID: 35641540
[TBL] [Abstract][Full Text] [Related]
7. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.
Élez E; Mulet-Margalef N; Sanso M; Ruiz-Pace F; Mancuso FM; Comas R; Ros J; Argilés G; Martini G; Sanz-Garcia E; Baraibar I; Salvà F; Noguerido A; Cuadra-Urteaga JL; Fasani R; Garcia A; Jimenez J; Aguilar S; Landolfi S; Hernández-Losa J; Braña I; Nuciforo P; Dienstmann R; Tabernero J; Salazar R; Vivancos A
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613564
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
[TBL] [Abstract][Full Text] [Related]
9. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.
Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M
JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992
[TBL] [Abstract][Full Text] [Related]
10. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
11. MHC Class II Expression Influences the Composition and Distribution of Immune Cells in the Metastatic Colorectal Cancer Microenvironment.
Griffith BD; Turcotte S; Lazarus J; Lima F; Bell S; Delrosario L; McGue J; Krishnan S; Oneka MD; Nathan H; Smith JJ; D'Angelica MI; Shia J; Di Magliano MP; Rao A; Frankel TL
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077630
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1/2 clinical trial.
Gögenur M; Balsevicius L; Bulut M; Colak N; Justesen TF; Fiehn AK; Jensen MB; Høst-Rasmussen K; Cappelen B; Gaggar S; Tajik A; Zahid JA; Bennedsen ALB; D'Ondes TDB; Raskov H; Sækmose SG; Hansen LB; Salanti A; Brix S; Gögenur I
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37172969
[TBL] [Abstract][Full Text] [Related]
13. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
14. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368
[TBL] [Abstract][Full Text] [Related]
15. Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors.
Takamori S; Takada K; Tagawa T; Toyokawa G; Hirai F; Yamashita N; Okamoto T; Oki E; Yoshizumi T; Oda Y; Maehara Y
Surg Oncol; 2018 Dec; 27(4):637-641. PubMed ID: 30449485
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
17. Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study.
Moretto R; Rossini D; Catteau A; Antoniotti C; Giordano M; Boccaccino A; Ugolini C; Proietti A; Conca V; Kassambara A; Pietrantonio F; Salvatore L; Lonardi S; Tamberi S; Tamburini E; Poma AM; Fieschi J; Fontanini G; Masi G; Galon J; Cremolini C
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37085190
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer.
Wei XL; Luo X; Sheng H; Wang Y; Chen DL; Li JN; Wang FH; Xu RH
J Transl Med; 2020 Dec; 18(1):475. PubMed ID: 33308232
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer.
Calik I; Calik M; Turken G; Ozercan IH; Dagli AF; Artas G; Sarikaya B
Medicina (Kaunas); 2019 Oct; 55(11):. PubMed ID: 31683723
[No Abstract] [Full Text] [Related]
20. PD-L1 Expression in Colorectal Adenocarcinoma Is Associated With the Tumor Immune Microenvironment and Epithelial-Mesenchymal Transition.
Secinti IE; Ozgur T; Dede I
Am J Clin Pathol; 2022 Oct; 158(4):506-515. PubMed ID: 35938631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]